June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Associations between Use of Cholesterol Medications and Glaucoma in the National Institutes of Health All of Us Research Program
Author Affiliations & Notes
  • Samuel Lee
    University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Megan E. Paul
    Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Ken Kitayama
    Department of Ophthalmology, Stein and Doheny Eye Institutes, University of California, Los Angeles, California, United States
    Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California, United States
  • Victoria L Tseng
    University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
    Department of Ophthalmology, Stein and Doheny Eye Institutes, University of California, Los Angeles, California, United States
  • Fei Yu
    Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, California, United States
  • Deyu Pan
    Department of Ophthalmology, Stein and Doheny Eye Institutes, University of California, Los Angeles, California, United States
  • Anne L Coleman
    University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
    Department of Ophthalmology, Stein and Doheny Eye Institutes, University of California, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Samuel Lee None; Megan Paul Research to Prevent Blindness Medical Student Fellowship, Code F (Financial Support); Ken Kitayama None; Victoria Tseng RPB/AAO Award for IRIS Registry Research, Code F (Financial Support), American Glaucoma Society MAPS Award, Code F (Financial Support); Fei Yu None; Deyu Pan None; Anne Coleman None
  • Footnotes
    Support  This work was supported by unrestricted grant funding from Research to Prevent Blindness to the UCLA Department of Ophthalmology.
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 88. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Samuel Lee, Megan E. Paul, Ken Kitayama, Victoria L Tseng, Fei Yu, Deyu Pan, Anne L Coleman; Associations between Use of Cholesterol Medications and Glaucoma in the National Institutes of Health All of Us Research Program. Invest. Ophthalmol. Vis. Sci. 2023;64(8):88.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To examine associations between use of cholesterol medications (CMs) and glaucoma in participants of the 2017-2022 National Institutes of Health All of Us Research Program (AoU) with hyperlipidemia.

Methods : The study population included adult participants aged >= 40 years who had hyperlipidemia, with electronic health record (EHR) and medication data in AoU. Hyperlipidemia was defined by EHR data. The exposure of interest was use of CMs, which included statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibrates, niacin, and omega-3 fatty acids. The outcome was the presence of glaucoma, which was defined by EHR data. Covariates included age, sex, race, level of education, income level, body mass index, smoking tobacco use, alcohol use, and history of diabetes mellitus, cardiovascular disease, and macular degeneration. Logistic regression modeling was used to examine the associations between use of CMs and glaucoma, adjusting for no or all study covariates.

Results : The study population included 173,525 participants with hyperlipidemia, 8,967 (5.2%) of whom had a diagnosis of glaucoma and 59,362 (34.2%) of whom used CMs. Compared to participants without use of CMs, those who used CMs had increased odds of glaucoma in both unadjusted (odds ratio [OR] = 2.21, 95% confidence interval [CI] = 2.06, 2.38) and fully adjusted (OR = 1.52, 95% CI = 1.37, 1.68) analyses.

Conclusions : In participants of the 2017-2022 AoU with hyperlipidemia, use of CMs was associated with increased likelihood of a diagnosis of glaucoma. Further investigations are needed to examine associations between cardiovascular disease, its treatments, and the risk of glaucoma.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×